Hansoh Pharmaceutical's Shenglai® (Pegcetacoplan) Receives First National Reimbursement Prescription for Renal Anemia Treatment

Hansoh Pharma is a leading innovation-driven pharmaceutical company in China, with subsidiaries including Hansoh Pharmaceuticals, Changzhou Hengbang Pharmaceuticals, and Hansoh Biomedicine. The company focuses on major therapeutic areas such as oncology, anti-infectives, central nervous system, metabolism, and autoimmune diseases, and is committed to improving the quality of human life through continuous innovation. To date, the company has launched seven innovative drugs, and the revenue share of innovative drugs has increased to 61.8%. Hansoh Pharma has consistently ranked among the top 100 global pharmaceutical companies for many years and has been among the top three best industrial enterprises in China's pharmaceutical R&D product lines. It is a key national high-tech enterprise and a national technology innovation demonstration enterprise.

END